Recombinant Soluble TNF-α Receptor Fusion Protein Therapy Reduces Insulin Resistance in Non-Diabetic Active Rheumatoid Arthritis Patients.
Chrong-Reen WangMing-Fei LiuPublished in: ACR open rheumatology (2020)
We observed an improvement in insulin sensitivity in nondiabetic active RA patients following 24-week recombinant soluble TNF-α receptor fusion protein therapy.
Keyphrases
- rheumatoid arthritis patients
- rheumatoid arthritis
- disease activity
- end stage renal disease
- newly diagnosed
- ejection fraction
- type diabetes
- prognostic factors
- systemic lupus erythematosus
- stem cells
- peritoneal dialysis
- randomized controlled trial
- ankylosing spondylitis
- clinical trial
- cell therapy
- bone marrow
- patient reported